FDA Panel: ' Little Merit ' in Sublingual Buprenorphine for Pain FDA Panel: ' Little Merit ' in Sublingual Buprenorphine for Pain

The FDA advisory committee voted overwhelmingly against the approval of a sublingual form of buprenorphine for treating moderate-to-severe acute pain, citing weak efficacy and safety concerns.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news